Merck buys rights to NewLink's experimental Ebola vaccine

Mon Nov 24, 2014 8:16am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Nov 24 (Reuters) - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.

Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.

Financial details were not disclosed.

The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug.

The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015. (Reporting by Vidya L Nathan in Bangalore; Editing by Siddharth Cavale)